Abstract
48
Control of Noncommunicable Diseases 2013-2020' 3 because they share key behavioural risk factors 49 amenable to public health action and together contribute to a major portion of global NCD burden. 4 
50
Although not currently identified as a separate target, there is undeniable evidence that kidney 51 disease is a key determinant of the poor health outcomes of diabetes and cardiovascular disease 52 (including hypertension). 4 Indeed, the WHO 'Global Action Plan' recognizes kidney disease as an 53 important factor in major NCD burden. 3 
55
Along with increased mortality and morbidity, skeletal muscle atrophy and skeletal muscle dysfunction 56 are well-documented consequences of these conditions. Driven by a complex torrent of factors such 57 as inflammation, disuse, ageing, and malnutrition, loss of skeletal muscle has been observed in 58 cardiovascular disease including chronic heart failure (CHF) 5 and cancer 6,7 -often termed 'cardiac' 59 and 'cancer' cachexia; diabetes 8 ; chronic respiratory disease such as chronic obstructive pulmonary 60 disease (COPD) 9,10 ; and chronic kidney disease (CKD). 11 
62
Disease-related muscle atrophy is an important clinical problem because loss of muscle mass and 63 therefore acquired skeletal muscle weakness can result in exercise and functional limitations, and 64 contribute to a poor quality of life (QoL). Importantly, and somewhat under-recognized, muscle also 65 plays a central role in whole-body protein metabolism, which is particularly important in the response 66 to stress. In particular, skeletal muscle serves as the principal reservoir for amino acids to maintain 67 protein synthesis in vital tissues and organs in the absence of amino acid absorption from the gut and 68 by providing hepatic gluconeogenic precursors 7 
143
This review will focus on the effect of home-based resistance training in patients with 144 noncommunicable (chronic) disease. Noncommunicable diseases will be defined as: cancer; 145 cardiovascular disease; diabetes mellitus (type 1 and type 2); CKD (including patients treated with 146 dialysis); and chronic respiratory disease (asthma, COPD, pulmonary hypertension). There will be no 147 restriction on age or sex in order to describe the full extent of the evidence related to the topic.
148
Studies exclusively investigating home-based resistance training in older adults will be excluded given 
173
The review will also explore the safety and adherence rates of home-based resistance training and 
185
for inclusion in this review will only come from peer-reviewed scientific publications or expert 186 consensus guidelines (described below). Evidence for inclusion in this review will not be restricted by 187 country or date to enable the full extent of available evidence to be mapped.
189
Types of studies
191
This scoping review will consider all types of quantitative and qualitative (if appropriate) study designs 192 and reviews (including narrative reviews and expert opinion articles termed as reviews). Quantitative 
220
Reference lists of articles selected for inclusion will be screened for additional relevant articles and 221 subject experts will be contacted to check for completeness in the list of articles identified by the 222 reviewers for inclusion. 
238
Following the search, all identified citations will be collated and uploaded into EndNote X7.3.1
239
(Clarivate Analytics, USA). After duplicates are removed, the titles and abstracts will be screened by may meet the inclusion criteria, and no exclusion criteria, will be retrieved in full. The full text of 242 selected articles will be assessed in detail by two independent reviewers. Full text articles that do not 243 meet the criteria for inclusion will be excluded and reasons for exclusion will be provided in an 244 appendix in the final review. The search results will be reported in full in the final review manuscript 245 and presented as a PRISMA flow diagram 46 . Disagreements between the reviewers will be resolved 246 through discussion or with a third reviewer -author T.J.W will have final say on inclusion.
248

Data extraction
250
Data from articles will be extracted into a charting form by two independent reviewers (as described 251 above). The data charted will include specific details about the author/s, date and type of publication, 
257
A draft charting form has been developed to ensure that appropriate data is extracted to enable the 258 review questions to be answered (Appendix III). This charting form will be initially tested by two 259 independent reviewers on two articles to check that all relevant information relating to the review 260 questions is extracted. If required, the form will continually be adapted during the review process and 261 the final version will be included in the final scoping review. Authors of included articles will be 262 contacted for clarification of information when necessary.
264
Calibration exercises
266
To prevent errors and ensure high inter-rater agreement, two 'calibration exercises' as recommended 267 by the PRISMA-ScR 43 will be performed. Firstly for the study selection process, the entire reviewer 268 team will examine 50 citations for initial title and abstract screening. Discrepancies in inclusion 269 between reviewers will be calculated and a roundtable discussion will be held to clarify any issues.
270
Refinements to the form will be made as required. A second exercise will be done if agreement 
